Literature DB >> 33985397

Development of 3-methyl/3-(morpholinomethyl)benzofuran derivatives as novel antitumor agents towards non-small cell lung cancer cells.

Mohammad M Al-Sanea1, Ghada H Al-Ansary2,3, Zainab M Elsayed4, Raed M Maklad5,6, Eslam B Elkaeed7,8, Mohamed A Abdelgawad1,9, Syed Nasir Abbas Bukhari1, Marwa M Abdel-Aziz10, Howayda Suliman11, Wagdy M Eldehna5.   

Abstract

As one of the most lethal malignancies, n class="Disease">lung cancer is considered to account for approximately one-fifth of all malignant tumours-related deaths worldwide. This study reports the synthesis and in vitro biological assessment of two sets of 3-methylbenzofurans (4a-d, 6a-c, 8a-c and 11) and 3-(morpholinomethyl)benzofurans (15a-c, 16a-b, 17a-b and 18) as potential anticancer agents towards non-small cell lung carcinoma A549 and NCI-H23 cell lines, with VEGFR-2 inhibitory activity. The target benzofuran-based derivatives efficiently inhibited the growth of both A549 and NCI-H23 cell lines with IC50 spanning in ranges 1.48-47.02 and 0.49-68.9 µM, respectively. The three most active benzofurans (4b, 15a and 16a) were further investigated for their effects on the cell cycle progression and apoptosis in A549 (for 4b) and NCI-H23 (for 15a and 16a) cell lines. Furthermore, benzofurans 4b, 15a and 16a displayed good VEGFR-2 inhibitory activity with IC50 equal 77.97, 132.5 and 45.4 nM, respectively.

Entities:  

Keywords:  Benzofuran-2-carbohydrazide; VEGFR-2 inhibitors; anticancer agents; lung cancer

Mesh:

Substances:

Year:  2021        PMID: 33985397      PMCID: PMC8128204          DOI: 10.1080/14756366.2021.1915302

Source DB:  PubMed          Journal:  J Enzyme Inhib Med Chem        ISSN: 1475-6366            Impact factor:   5.051


  33 in total

1.  About brominated coumarone derivatives and a new preparation of coumaronyl-3-acetic acid.

Authors:  W GRUBENMANN; H ERLENMEYER
Journal:  Helv Chim Acta       Date:  1948       Impact factor: 2.164

2.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

3.  Benzofuran-Based Carboxylic Acids as Carbonic Anhydrase Inhibitors and Antiproliferative Agents against Breast Cancer.

Authors:  Wagdy M Eldehna; Alessio Nocentini; Zainab M Elsayed; Tarfah Al-Warhi; Nada Aljaeed; Ohoud J Alotaibi; Mohammad M Al-Sanea; Hatem A Abdel-Aziz; Claudiu T Supuran
Journal:  ACS Med Chem Lett       Date:  2020-03-18       Impact factor: 4.345

4.  Recent advances in targeted small-molecule inhibitor therapy for non-small-cell lung cancer-An update.

Authors:  Shubham Atal; Pravin Asokan; Ratinder Jhaj
Journal:  J Clin Pharm Ther       Date:  2020-02-18       Impact factor: 2.512

Review 5.  Bioactive Benzofuran derivatives: A review.

Authors:  Hena Khanam
Journal:  Eur J Med Chem       Date:  2014-11-22       Impact factor: 6.514

6.  Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors.

Authors:  Michele McTigue; Brion William Murray; Jeffrey H Chen; Ya-Li Deng; James Solowiej; Robert S Kania
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-17       Impact factor: 11.205

7.  A Novel Benzofuran Derivative Moracin N Induces Autophagy and Apoptosis Through ROS Generation in Lung Cancer.

Authors:  Chengcheng Gao; Xin Sun; Zhipan Wu; Huahua Yuan; Haote Han; Hongliang Huang; Yuhan Shu; Mengting Xu; Ruilan Gao; Shouxin Li; Jianbin Zhang; Jingkui Tian
Journal:  Front Pharmacol       Date:  2020-05-12       Impact factor: 5.810

8.  Novel benzofuran-based sulphonamides as selective carbonic anhydrases IX and XII inhibitors: synthesis and in vitro biological evaluation.

Authors:  Mohamed A Abdelrahman; Wagdy M Eldehna; Alessio Nocentini; Hany S Ibrahim; Hadia Almahli; Hatem A Abdel-Aziz; Sahar M Abou-Seri; Claudiu T Supuran
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

9.  Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3β inhibitors targeting breast cancer: design, synthesis, biological evaluation, and in silico studies.

Authors:  Wagdy M Eldehna; Sara T Al-Rashood; Tarfah Al-Warhi; Razan O Eskandrani; Amal Alharbi; Ahmed M El Kerdawy
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

10.  Benzofuran-appended 4-aminoquinazoline hybrids as epidermal growth factor receptor tyrosine kinase inhibitors: synthesis, biological evaluation and molecular docking studies.

Authors:  Malose J Mphahlele; Marole M Maluleka; Abimbola Aro; Lyndy J McGaw; Yee Siew Choong
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

View more
  9 in total

1.  1,3,4-Oxadiazole-naphthalene hybrids as potential VEGFR-2 inhibitors: design, synthesis, antiproliferative activity, apoptotic effect, and in silico studies.

Authors:  Mohamed Hagras; Marwa A Saleh; Rogy R Ezz Eldin; Abdelrahman A Abuelkhir; Emad Gamil Khidr; Ahmed A El-Husseiny; Hesham A El-Mahdy; Eslam B Elkaeed; Ibrahim H Eissa
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.051

2.  Design, Synthesis, In Silico and In Vitro Studies of New Immunomodulatory Anticancer Nicotinamide Derivatives Targeting VEGFR-2.

Authors:  Reda G Yousef; Wagdy M Eldehna; Alaa Elwan; Abdelaziz S Abdelaziz; Ahmed B M Mehany; Ibraheem M M Gobaara; Bshra A Alsfouk; Eslam B Elkaeed; Ahmed M Metwaly; Ibrahim H Eissa
Journal:  Molecules       Date:  2022-06-24       Impact factor: 4.927

3.  Discovery of new nicotinamides as apoptotic VEGFR-2 inhibitors: virtual screening, synthesis, anti-proliferative, immunomodulatory, ADMET, toxicity, and molecular dynamic simulation studies.

Authors:  Reda G Yousef; Albaraa Ibrahim; Mohamed M Khalifa; Wagdy M Eldehna; Ibraheem M M Gobaara; Ahmed B M Mehany; Eslam B Elkaeed; Aisha A Alsfouk; Ahmed M Metwaly; Ibrahim H Eissa
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

4.  Design, synthesis and biological evaluation of a series of dianilinopyrimidines as EGFR inhibitors.

Authors:  Longjia Yan; Qin Wang; Li Liu; Yi Le
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.051

5.  Design, synthesis, and anti-cancer evaluation of new pyrido[2,3-d]pyrimidin-4(3H)-one derivatives as potential EGFRWT and EGFRT790M inhibitors and apoptosis inducers.

Authors:  Heba S A Elzahabi; Eman S Nossier; Rania A Alasfoury; May El-Manawaty; Sara M Sayed; Eslam B Elkaeed; Ahmed M Metwaly; Mohamed Hagras; Ibrahim H Eissa
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

6.  Discovery of new 1H-pyrazolo[3,4-d]pyrimidine derivatives as anticancer agents targeting EGFRWT and EGFRT790M.

Authors:  Ahmed A Gaber; Mohamed Sobhy; Abdallah Turky; Hanan Gaber Abdulwahab; Ahmed A Al-Karmalawy; Mostafa A Elhendawy; Mohamed M Radwan; Eslam B Elkaeed; Ibrahim M Ibrahim; Heba S A Elzahabi; Ibrahim H Eissa
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

7.  The Anticancer Effects of the Pro-Apoptotic Benzofuran-Isatin Conjugate (5a) Are Associated With p53 Upregulation and Enhancement of Conventional Chemotherapeutic Drug Efficiency in Colorectal Cancer Cell Lines.

Authors:  Mansoor-Ali Vaali-Mohammed; Maha-Hamadien Abdulla; Sabine Matou-Nasri; Wagdy M Eldehna; M Meeramaideen; Eslam B Elkaeed; Mohammed El-Watidy; Noura S Alhassan; Khayal Alkhaya; Omar Al Obeed
Journal:  Front Pharmacol       Date:  2022-08-15       Impact factor: 5.988

8.  Anti-cancer and immunomodulatory evaluation of new nicotinamide derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: in vitro and in silico studies.

Authors:  Reda G Yousef; Alaa Elwan; Ibraheem M M Gobaara; Ahmed B M Mehany; Wagdy M Eldehna; Souad A El-Metwally; Bshra A Alsfouk; Eslam B Elkaeed; Ahmed M Metwaly; Ibrahim H Eissa
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

9.  Discovery of New VEGFR-2 Inhibitors: Design, Synthesis, Anti-Proliferative Evaluation, Docking, and MD Simulation Studies.

Authors:  Eslam B Elkaeed; Reda G Yousef; Mohamed M Khalifa; Albaraa Ibrahim; Ahmed B M Mehany; Ibraheem M M Gobaara; Bshra A Alsfouk; Wagdy M Eldehna; Ahmed M Metwaly; Ibrahim H Eissa; Mohamed Ayman El-Zahabi
Journal:  Molecules       Date:  2022-09-21       Impact factor: 4.927

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.